Atea Pharmaceuticals, Inc. director Bruce Polsky filed a Form 144 notice of proposed sale of 8,750 shares of common stock on November 19, 2026, disclosing an aggregate market value of $35,299.25.
Key Highlights
- Proposed sale: Bruce Polsky, a director of Atea Pharmaceuticals, Inc., intends to sell 8,750 shares of common stock with an aggregate market value of $35,299.25.
- Acquisition date: The 8,750 shares were acquired on November 16, 2026, via exercise of shares from the issuer, with cash payment on the same date.
- Approximate sale date: The filing lists November 19, 2026, as the approximate date of sale, through Morgan Stanley Smith Barney LLC Executive Financial Services in New York.
- Shares outstanding: According to the filing, 80,304,145 shares of common stock were outstanding at the time of the notice.
- Prior three-month sales: Polsky sold 14,254 shares on November 16, 2026 (gross proceeds $60,840.35), 8,720 shares on November 17, 2026 (gross proceeds $35,155.55), and 18,252 shares on November 18, 2026 (gross proceeds $72,099.05).
Polsky's Proposed Sale and Recent Transaction Activity at Atea Pharmaceuticals
According to the Form 144 filing dated November 19, 2026, Bruce Polsky, identified as a director of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR), is proposing to sell 8,750 shares of the company's common stock. The filing identifies Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY, as the named broker for the proposed transaction. The aggregate market value of the shares proposed for sale is listed as $35,299.25.
The filing discloses that the 8,750 shares to be sold were acquired on November 16, 2026, through an exercise of shares from the issuer, with payment made in cash on the same date. Atea Pharmaceuticals, Inc. is listed on NASDAQ and is headquartered at 225 Franklin Street, Suite 2100, Boston, Massachusetts 02110.
The filing also details Polsky's sales of Atea Pharmaceuticals common stock over the prior three months. On November 16, 2026, he sold 14,254 shares with gross proceeds of $60,840.35. On November 17, 2026, he sold 8,720 shares with gross proceeds of $35,155.55. On November 18, 2026, he sold 18,252 shares with gross proceeds of $72,099.05. These prior sales are reported at the same address listed for Polsky: 225 Franklin Street, Suite 2100, Boston, MA 02110.
What Was Disclosed
Bruce Polsky, a director at Atea Pharmaceuticals, Inc., filed a Form 144 on November 19, 2026, to propose the sale of 8,750 common shares valued at $35,299.25, acquired via exercise on November 16, 2026, and disclosed three prior sales totaling 41,226 shares in the preceding days.



Please wait processing your request...